Valganciclovir Dose Appropriateness Based on Estimated Glomerular Filtration Rate in Kidney Transplant Recipients: A Real-World Study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Introduction: Rapid fluctuations in estimated glomerular filtration rate (eGFR) during the early post-transplant period can complicate valganciclovir dosing, which requires adjustment according to renal function. This study aimed to evaluate the appropriateness of valganciclovir prophylaxis dosing based on eGFR in kidney transplant recipients and to examine its associations with cytomegalovirus (CMV) DNAemia, hematological parameters, and changes in kidney function. Materials and Methods: This single-center retrospective study included 71 adult kidney transplant recipients who underwent transplantation between October 2023 and May 2025 and received valganciclovir prophylaxis for at least 3 months. Dose appropriateness was evaluated using Chronic Kidney Disease Epidemiology Collaboration-based eGFR values (mL/min/1.73 m 2 ) automatically reported by the hospital laboratory, consistent with routine clinical practice at our center. Hematological parameters and eGFR values measured at prophylaxis initiation and completion were compared. CMV DNA polymerase chain reaction surveillance was conducted every 2 weeks during prophylaxis and monthly thereafter through 1 year after transplantation. Results: The median patient age was 40 years [interquartile range (IQR), 32–52.5], and 63.4% were male. At prophylaxis initiation, 35 (49.3%) patients received an eGFR-appropriate valganciclovir dose, whereas 34/71 (47.9%) received a higher-than-recommended dose and 2/71 (2.8%) received a lower-than-recommended dose. By prophylaxis completion, the proportion receiving an appropriate dose had increased to 66/71 (93.0%); 5/71 (7.0%) continued to receive a higher-than-recommended dose, and none received a lower-than-recommended dose. Late-onset CMV DNAemia developed in 7 (9.9%) patients at a median of 6 months (IQR, 5–9) after transplantation. Among patients who initially received eGFR-inappropriate dosing and had complete paired data, white blood cell count and neutrophil counts decreased significantly, whereas lymphocyte counts and eGFR increased significantly during prophylaxis (all p < 0.001). At prophylaxis completion, however, hematological parameters did not differ significantly between patients receiving appropriate and inappropriate doses. Conclusion: eGFR-inappropriate valganciclovir dosing was frequent at prophylaxis initiation but decreased substantially over the course of follow-up. Because eGFR can change dynamically during the early post-transplant period, valganciclovir dosing should be reassessed regularly to ensure continued dose appropriateness. Multidisciplinary monitoring and antiviral stewardship strategies may help maintain appropriate valganciclovir dosing throughout prophylaxis.
Institutions: Sağlık Bilimleri Üniversitesi, Ankara Etlik City Hospital
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Keywords: valganciclovir, dose appropriateness, kidney transplant recipients, estimated glomerular filtration rate, antiviral prophylaxis, cytomegalovirus DNAemia, renal function, hematological parameters, neutropenia, lymphopenia, dose adjustment, immunosuppression, post-transplant period, real-world evidence
Open Access status: diamond
OpenAlex ID: W7236667535
